ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

NCAB Seeks Greater flexibility In Grants Target To Aid P01s

May 31, 1991

Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial

October 26, 2012

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014

DRCA Board Okays Concepts For Five Contract Projects

June 25, 1981

Half Of Mexican-Origin Women With Breast Cancer Diagnosed Before Age 50, Study Finds

September 24, 2010

When Screening Mammography Meets Health Care Reform, Opinions Proliferate

February 4, 1994